{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,16]],"date-time":"2026-08-16T23:25:13Z","timestamp":1786922713987,"version":"build-2736575974"},"reference-count":31,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,6,10]],"date-time":"2026-06-10T00:00:00Z","timestamp":1781049600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T00:00:00Z","timestamp":1786924800000},"content-version":"vor","delay-in-days":68,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Ophthalmol"],"DOI":"10.1186\/s12886-026-05022-1","type":"journal-article","created":{"date-parts":[[2026,6,10]],"date-time":"2026-06-10T09:56:10Z","timestamp":1781085370000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Comparison of topical nepafenac 0.1% and 0.3% for the treatment of pseudophakic cystoid macular edema following cataract surgery"],"prefix":"10.1186","volume":"26","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-2638-0569","authenticated-orcid":false,"given":"Semih","family":"\u00c7akmak","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0003-2973-2686","authenticated-orcid":false,"given":"Miray","family":"S\u00f6ylemez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5949-4082","authenticated-orcid":false,"given":"Zafer","family":"Cebeci","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4155-0407","authenticated-orcid":false,"given":"Gurkan","family":"Erdogan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7967-825X","authenticated-orcid":false,"given":"Emre","family":"Alt\u0131nkurt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0889-7599","authenticated-orcid":false,"given":"\u015eerife","family":"Bayraktar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,6,10]]},"reference":[{"issue":"1","key":"5022_CR1","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1097\/00055735-200002000-00010","volume":"11","author":"L Rossetti","year":"2000","unstructured":"Rossetti L, Autelitano A. Cystoid macular edema following cataract surgery. Curr Opin Ophthalmol Feb. 2000;11(1):65\u201372. https:\/\/doi.org\/10.1097\/00055735-200002000-00010.","journal-title":"Curr Opin Ophthalmol Feb"},{"issue":"10","key":"5022_CR2","doi-asserted-by":"publisher","first-page":"1005","DOI":"10.1016\/j.ophtha.2023.06.001","volume":"130","author":"M Iftikhar","year":"2023","unstructured":"Iftikhar M, Dun C, Schein OD, Lum F, Woreta F. Cystoid Macular Edema after Cataract Surgery in the United States: IRIS\u00ae Registry (Intelligent Research in Sight) Analysis. Ophthalmology Oct. 2023;130(10):1005\u201314. https:\/\/doi.org\/10.1016\/j.ophtha.2023.06.001.","journal-title":"Ophthalmology Oct"},{"key":"5022_CR3","doi-asserted-by":"crossref","unstructured":"Smarlamaki R, Koutsoumpi E-A, Psaltopoulou T, et al. Risk factors and cumulative incidence of cystoid macular edema after simple cataract surgery: a systematic review and meta-analysis. Cureus. 2025;17(5).","DOI":"10.7759\/cureus.84212"},{"issue":"2","key":"5022_CR4","doi-asserted-by":"publisher","first-page":"316","DOI":"10.1016\/j.ophtha.2015.10.001","volume":"123","author":"CJ Chu","year":"2016","unstructured":"Chu CJ, Johnston RL, Buscombe C, Sallam AB, Mohamed Q, Yang YC. Risk Factors and Incidence of Macular Edema after Cataract Surgery: A Database Study of 81984 Eyes. Ophthalmology Feb. 2016;123(2):316\u201323. https:\/\/doi.org\/10.1016\/j.ophtha.2015.10.001.","journal-title":"Ophthalmology Feb"},{"key":"5022_CR5","doi-asserted-by":"crossref","unstructured":"Arevalo JF, Fernandez CF, Arevalo FA. Pseudophakic cystoid macular edema. More Phaco Nightmares. CRC Press. 2024:339\u201348.","DOI":"10.1201\/9781003525097-34"},{"issue":"19","key":"5022_CR6","doi-asserted-by":"publisher","first-page":"4375","DOI":"10.3390\/jcm10194375","volume":"10","author":"M Orski","year":"2021","unstructured":"Orski M, Gaw\u0119cki M. Current management options in Irvine\u2013Gass syndrome: a systemized review. J Clin Med. 2021;10(19):4375.","journal-title":"J Clin Med"},{"issue":"4","key":"5022_CR7","doi-asserted-by":"publisher","first-page":"371","DOI":"10.1023\/A:1007001131987","volume":"24","author":"T-L Ke","year":"2000","unstructured":"Ke T-L, Graff G, Spellman JM, Yanni JM. Nepafenac, a unique nonsteroidal prodrug with potential utility in the treatment of trauma-induced ocular inflammation: II. In vitro bioactivation and permeation of external ocular barriers. Inflammation. 2000;24(4):371\u201384.","journal-title":"Inflammation"},{"issue":"3","key":"5022_CR8","doi-asserted-by":"publisher","first-page":"807","DOI":"10.4103\/ijo.IJO_2401_21","volume":"70","author":"N Bardoloi","year":"2022","unstructured":"Bardoloi N, Sarkar S, Burgute PS, et al. Comparison of once daily dose of 0.3% nepafenac alone and three times dose of 0.1% nepafenac alone in pain and inflammation control after phacoemulsification. Indian J Ophthalmol. 2022;70(3):807\u201312.","journal-title":"Indian J Ophthalmol"},{"key":"5022_CR9","doi-asserted-by":"crossref","unstructured":"Giarmoukakis AK, Blazaki SV, Bontzos GC, et al. Efficacy of topical nepafenac 0.3% in the management of postoperative cystoid macular edema. Ther Clin Risk Manag. 2020:1067\u201374.","DOI":"10.2147\/TCRM.S271184"},{"issue":"6","key":"5022_CR10","doi-asserted-by":"publisher","first-page":"776","DOI":"10.1016\/j.ophtha.2017.01.036","volume":"124","author":"RP Singh","year":"2017","unstructured":"Singh RP, Lehmann R, Martel J, et al. Nepafenac 0.3% after cataract surgery in patients with diabetic retinopathy: results of 2 randomized phase 3 studies. Ophthalmology. 2017;124(6):776\u201385.","journal-title":"Ophthalmology"},{"issue":"Suppl 3","key":"5022_CR11","doi-asserted-by":"publisher","first-page":"S424","DOI":"10.4103\/IJO.IJO_2916_24","volume":"73","author":"YB Akbas","year":"2025","unstructured":"Akbas YB, Aydin FO, Kelebek M, et al. Comparison of topical nepafenac 0.1% and 0.3% on aqueous flare and macular thickness in patients with pseudoexfoliation following cataract surgery. Indian J Ophthalmol. 2025;73(Suppl 3):S424\u20137.","journal-title":"Indian J Ophthalmol"},{"issue":"6","key":"5022_CR12","doi-asserted-by":"publisher","first-page":"831","DOI":"10.1001\/archopht.1993.01090060119035","volume":"111","author":"LT Chylack Jr","year":"1993","unstructured":"Chylack LT Jr., Wolfe JK, Singer DM, et al. The Lens Opacities Classification System III. The Longitudinal Study of Cataract Study Group. Arch Ophthalmol Jun. 1993;111(6):831\u20136. https:\/\/doi.org\/10.1001\/archopht.1993.01090060119035.","journal-title":"Arch Ophthalmol Jun"},{"key":"5022_CR13","doi-asserted-by":"publisher","first-page":"21090","DOI":"10.1038\/srep21090","volume":"6","author":"R Agrawal","year":"2016","unstructured":"Agrawal R, Gupta P, Tan KA, Cheung CM, Wong TY, Cheng CY. Choroidal vascularity index as a measure of vascular status of the choroid: Measurements in healthy eyes from a population-based study. Sci Rep Feb 12. 2016;6:21090. https:\/\/doi.org\/10.1038\/srep21090.","journal-title":"Sci Rep Feb 12"},{"key":"5022_CR14","doi-asserted-by":"crossref","unstructured":"Campos A, Mota C, Cruz H, Sousa JP. Pseudophakic macular edema: Review and new insights on treatment and prophylaxis. Surv Ophthalmol. 2025.","DOI":"10.1016\/j.survophthal.2025.11.001"},{"key":"5022_CR15","doi-asserted-by":"publisher","unstructured":"Ferro Desideri L, Arun K, Bernardi E, Sagurski N, Anguita R, Incidence, pathogenesis, risk factors, and treatment of cystoid macula oedema following cataract surgery: a systematic review. Diagnostics (Basel) Mar. 2025;10(6). https:\/\/doi.org\/10.3390\/diagnostics15060667.","DOI":"10.3390\/diagnostics15060667"},{"key":"5022_CR16","doi-asserted-by":"crossref","unstructured":"Sivaprasad S, Bunce C, Crosby-Nwaobi R. Non\u2010steroidal anti\u2010inflammatory agents for treating cystoid macular oedema following cataract surgery. Cochrane Database Syst Reviews. 2012;(2).","DOI":"10.1002\/14651858.CD004239.pub3"},{"issue":"4","key":"5022_CR17","doi-asserted-by":"publisher","first-page":"513","DOI":"10.3109\/09273948.2016.1147587","volume":"25","author":"B Y\u00fcksel","year":"2017","unstructured":"Y\u00fcksel B, Uzunel UD, Kerci SG, Sa\u011fban L, K\u00fcsbeci T, \u00d6rsel T. Comparison of subtenon triamcinolone acetonide injection with topical nepafenac for the treatment of pseudophakic cystoid macular edema. Ocul Immunol Inflamm. 2017;25(4):513\u20139.","journal-title":"Ocul Immunol Inflamm"},{"issue":"7","key":"5022_CR18","doi-asserted-by":"publisher","first-page":"814","DOI":"10.1080\/02713683.2019.1701686","volume":"45","author":"L Ilveskoski","year":"2020","unstructured":"Ilveskoski L, Taipale C, Tuuminen R. Anti-inflammatory medication of cataract surgery in pseudoexfoliation syndrome\u2013NSAID is needed. Curr Eye Res. 2020;45(7):814\u20139.","journal-title":"Curr Eye Res"},{"issue":"9","key":"5022_CR19","doi-asserted-by":"publisher","first-page":"1550","DOI":"10.1016\/j.jcrs.2007.05.013","volume":"33","author":"BA Henderson","year":"2007","unstructured":"Henderson BA, Kim JY, Ament CS, Ferrufino-Ponce ZK, Grabowska A, Cremers SL. Clinical pseudophakic cystoid macular edema: risk factors for development and duration after treatment. J Cataract Refract Surg. 2007;33(9):1550\u20138.","journal-title":"J Cataract Refract Surg"},{"issue":"5","key":"5022_CR20","doi-asserted-by":"publisher","first-page":"909","DOI":"10.1007\/s00417-018-3954-4","volume":"256","author":"F Schaub","year":"2018","unstructured":"Schaub F, Adler W, Enders P, et al. Preexisting epiretinal membrane is associated with pseudophakic cystoid macular edema. Graefes Arch Clin Exp Ophthalmol. 2018;256(5):909\u201317.","journal-title":"Graefes Arch Clin Exp Ophthalmol"},{"issue":"8","key":"5022_CR21","doi-asserted-by":"publisher","first-page":"1224","DOI":"10.1080\/09273948.2019.1634215","volume":"27","author":"D Bellocq","year":"2019","unstructured":"Bellocq D, Mathis T, Voirin N, et al. Incidence of Irvine Gass syndrome after phacoemulsification with spectral-domain optical coherence tomography. Ocul Immunol Inflamm. 2019;27(8):1224\u201331.","journal-title":"Ocul Immunol Inflamm"},{"issue":"2","key":"5022_CR22","doi-asserted-by":"publisher","first-page":"584","DOI":"10.1038\/s41433-020-0908-y","volume":"35","author":"O-O Erikitola","year":"2021","unstructured":"Erikitola O-O, Siempis T, Foot B, Lockington D. The incidence and management of persistent cystoid macular oedema following uncomplicated cataract surgery\u2014a Scottish Ophthalmological Surveillance Unit study. Eye. 2021;35(2):584\u201391.","journal-title":"Eye"},{"issue":"2","key":"5022_CR23","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1159\/000331277","volume":"227","author":"C Lobo","year":"2012","unstructured":"Lobo C. Pseudophakic cystoid macular edema. Ophthalmologica. 2012;227(2):61\u20137.","journal-title":"Ophthalmologica"},{"issue":"4","key":"5022_CR24","doi-asserted-by":"publisher","first-page":"626","DOI":"10.1016\/j.jcrs.2013.09.018","volume":"40","author":"AA Hunter","year":"2014","unstructured":"Hunter AA, Modjtahedi SP, Long K, et al. Improving visual outcomes by preserving outer retina morphology in eyes with resolved pseudophakic cystoid macular edema. J Cataract Refract Surg Apr. 2014;40(4):626\u201331. https:\/\/doi.org\/10.1016\/j.jcrs.2013.09.018.","journal-title":"J Cataract Refract Surg Apr"},{"issue":"6","key":"5022_CR25","doi-asserted-by":"publisher","first-page":"827","DOI":"10.4103\/ijo.IJO_735_17","volume":"66","author":"S Sengupta","year":"2018","unstructured":"Sengupta S, Vasavada D, Pan U, Sindal M. Factors predicting response of pseudophakic cystoid macular edema to topical steroids and nepafenac. Indian J Ophthalmol. 2018;66(6):827\u201330.","journal-title":"Indian J Ophthalmol"},{"issue":"2","key":"5022_CR26","first-page":"258","volume":"12","author":"H Guclu","year":"2019","unstructured":"Guclu H, Gurlu VP. Comparison of topical nepafenac 0.1% with intravitreal dexamethasone implant for the treatment of Irvine-Gass syndrome. Int J Ophthalmol. 2019;12(2):258.","journal-title":"Int J Ophthalmol"},{"key":"5022_CR27","doi-asserted-by":"crossref","unstructured":"Hariprasad SM, Akduman L, Clever JA, Ober M, Recchia FM, Mieler WF. Treatment of cystoid macular edema with the new-generation NSAID nepafenac 0.1%. Clin Ophthalmol. 2009:147\u201354.","DOI":"10.2147\/OPTH.S4684"},{"key":"5022_CR28","doi-asserted-by":"publisher","first-page":"58","DOI":"10.1016\/j.exer.2015.10.009","volume":"145","author":"JE Chastain","year":"2016","unstructured":"Chastain JE, Sanders ME, Curtis MA, et al. Distribution of topical ocular nepafenac and its active metabolite amfenac to the posterior segment of the eye. Exp Eye Res. 2016;145:58\u201367.","journal-title":"Exp Eye Res"},{"issue":"8","key":"5022_CR29","doi-asserted-by":"publisher","first-page":"1629","DOI":"10.1097\/IAE.0000000000001747","volume":"38","author":"E Fleissig","year":"2018","unstructured":"Fleissig E, Cohen S, Iglicki M, Goldstein M, Zur D. Changes in choroidal thickness in clinically significant pseudophakic cystoid macular edema. Retina. 2018;38(8):1629\u201335.","journal-title":"Retina"},{"issue":"1","key":"5022_CR30","doi-asserted-by":"publisher","first-page":"21090","DOI":"10.1038\/srep21090","volume":"6","author":"R Agrawal","year":"2016","unstructured":"Agrawal R, Gupta P, Tan K-A, Cheung CMG, Wong T-Y, Cheng C-Y. Choroidal vascularity index as a measure of vascular status of the choroid: measurements in healthy eyes from a population-based study. Sci Rep. 2016;6(1):21090.","journal-title":"Sci Rep"},{"key":"5022_CR31","unstructured":"Loh NC, Rojas-Carabali W, Lim YH et al. Choroidal vascularity index as a marker of health and disease: systematic review and meta-analyses. Surv Ophthalmol. 2025."}],"container-title":["BMC Ophthalmology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12886-026-05022-1","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12886-026-05022-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12886-026-05022-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,16]],"date-time":"2026-08-16T22:51:47Z","timestamp":1786920707000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s12886-026-05022-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6,10]]},"references-count":31,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["5022"],"URL":"https:\/\/doi.org\/10.1186\/s12886-026-05022-1","relation":{},"ISSN":["1471-2415"],"issn-type":[{"value":"1471-2415","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,6,10]]},"assertion":[{"value":"9 February 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 June 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 June 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The study was conducted in accordance with the principles of the Declaration of Helsinki and was approved by the Istanbul University, Istanbul Faculty of Medicine Clinical Research Ethics Committee (Approval date and no: January 12, 2026; No. 3829850). All participants provided written informed consent before cataract surgery and subtenon injections.","order":1,"name":"Ethics","label":"Ethics approval and consent to participate","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","label":"Consent for publication","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The corresponding author is a member of the Editorial Board of BMC Ophthalmology and had no role in the editorial handling or peer review process of this manuscript.","order":3,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Declarations"}}],"article-number":"494"}}